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Human tumor necrosis factor α (hTNFα), a pleiotropic cytokine with activities
ranging from host defense mechanisms in infection and injury to severe toxicity
in septic shock or other related diseases, is a promising target for drug screening.
Using the SELEX (systematic evolution of ligands by exponential enrichment) pro-
cess, we isolated oligonucleotide ligands (aptamers) with high affinities for hTNFα.
Aptamers were selected from a starting pool of 40 randomized sequences composed
of about 1015 RNA molecules. Representative aptamers were truncated to the min-
imal length with high affinity for hTNFα and were further modified by replacement
of 2′-OH with 2′-F and 2′-NH2 at all ribopurine positions. These modified RNA
aptamers were resistant to nuclease. The specificity of these aptamers for hTNFα
was confirmed, and their activity to inhibit the cytotoxicity of hTNFα on mouse
L929 cells was determined. Results demonstrated that four 2′-NH2-modified ap-
tamers bound to hTNFα with high affinity and blocked the binding of hTNFα to its
receptor, thus protecting the L929 cells from the cytotoxicity of hTNFα. Oligonu-
cleotide aptamers described here are potential therapeutics and diagnostics for
hTNFα-related diseases.
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Introduction
Tumor necrosis factor (TNF) is a pro-inflammatory
cytokine that participates in the regulation of immune
defense against various pathogens and the recovery
from injury. It plays a central role in the develop-
ment of many inflammatory diseases. There is clear
evidence that aberration in TNF production in vivo
results in diseases, such as multi-organ inflammation,
rheumatoid arthritis (RA), multiple sclerosis, and in-
flammatory bowel disease (1 ). It is widely accepted
that TNF plays important part in pathophysiology
by directing its two transmembrane receptors to de-
liver signals of cellular proliferation, differentiation or
apoptosis. Attempts to identify biological agents that
could protect the body against these pathological ef-
fects led to the discovery of soluble TNF receptors
and monoclonal antibodies, which competitively in-
hibit the binding of TNF to cell surface receptors and
thus block TNF bio-activity (2 , 3 ). Blockade of TNF
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in rheumatoid arthritis or inflammatory bowel dis-
ease, although so far impressively beneficial for the
majority of patients, has led in some cases to a signif-
icant incidence of drug induced anti-dsDNA produc-
tion and lupus, and manifestations of neuroinflam-
matory diseases (4–6). Although these protein drugs
provide good therapeutic effect, there are still disad-
vantages. Firstly, the process of protein preparation
is complicated and expensive; secondly, the protein
drugs have high molecular weight and are difficult to
get to the target tissues because of its poor perme-
ability; thirdly, the blood clearance is so low that it is
hard to excrete, which results in its accumulation in
the body and causes side effect; finally, due to the in-
troduction of the exogenous proteins and the change
of structure, the proteins have immunogenicity, once
repeatedly used, it induces antibody formation.
Nucleic acids, as a function of their primary struc-
ture, fold into complex three-dimensional structure
with great diversity of binding specificities. Us-
ing the SELEX (systematic evolution of ligands by
exponential enrichment) process, oligonucleotides lig-
ands (aptamers) may be efficiently isolated from enor-
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mous randomized libraries of RNA, DNA, or modified
nucleic acids that bind with high affinity and speci-
ficity to a wide range of selected molecular targets
(7 ). Aptamers can be highly potent antagonists of
specific protein-protein interactions with following ad-
vantages. They do not depend on animals, cells, or
even in vivo conditions produced by chemical synthe-
sis with extreme accuracy and reproducibility. Once
denatured, functional aptamers could be regenerated
easily within minutes. They are stable to long-term
storage and can be transported at ambient tempera-
ture (8 ). The potential utility of aptamers as thera-
peutic or diagnostic agents is considerably enhanced
by chemical modifications that lend resistance to nu-
clease attack. In particular, substitution at the 2′
position of ribonucleotides with 2′-amino (2′-NH2),
2′-fluoro (2′-F), or a variety of 2′-O-alkyl moieties
confers resistance to ribonucleases that utilize the 2′-
OH group for cleavage of the adjacent phosphodiester
bond (9 ). This technology has been applied to a wide
range of targets including growth factors, enzymes of
HIV, and inflammation-inducing enzymes. The first
aptamer that has proceeded to Phase II clinical trial is
NX-1838, an injectable angiogenesis inhibitor used to
treat macular degeneration-induced blindness (10 ).
Here we report the screening of human TNFα
(hTNFα) aptamers from an oligonucleotide library
with 40 randomized sequences composed of about
1015 RNA molecules. Representative aptamers were
truncated to minimal sequence with high binding ac-
tivity and modified by replacement of 2′-OH with 2′-
F and 2′-NH2 at all ribopurines. Aptamers described
here represent an initial set of lead compounds in our
ongoing effort toward the development of potent and
specific hTNFα antagonists.
Results
Cloning and sequencing of selected
oligonucleotides
RNA aptamers for hTNFα were isolated from an
oligonucleotide library with 40 randomized sequences.
Twelve rounds of selection were performed, and
enzyme-linked oligonucleotide assay (ELONA) was
used to evaluate the binding affinity between the pro-
duction of every round and hTNFα (Figure 1). As no
further improvement in binding affinity was observed
after Round 12, sequences in the pool of the 12 rounds
were cloned respectively, and then plasmids of the 40
clones were purified. Biotin-labeled RNA aptamers
Fig. 1 Binding affinity analysis of aptamers with ELONA.
Oligonucleotides were labeled by biotin, and 5 µg/mL
hTNFα was coated in every well. The binding affinity
for hTNFα was determined by ELONA as described in
Materials and Methods.
were prepared by in vitro transcription. The binding
affinity was evaluated by filter binding assay, and 20
clones with higher affinity for hTNFα were sequenced
among the 40 clones (Table 1). All the sequences were
different from each other. There was no signal in the
negative control of RNA library and hTNFα, neither
in the blank control of RNA aptamer 1 alone.
Analysis of selected oligonucleotides
Ligands containing the primary structure motif of
GGAG/AAAGU/AG were Aptamers 5, 8, 9, 15, and
20. Aptamers 5, 8, 9, 15, and 16 shared the conserved
primary structure motifs CGNAGAA. Aptamers 1,
5, 8, 9, and 15 shared the conserved primary struc-
ture motifs GAG/AAAG. Ligands containing the pri-
mary structure motif of GAG/AUUA were Aptamers
5, 6, 13, 14, and 15. Aptamers 6, 8, 9, 10, 12, 18,
19, and 20 shared the same motif of CUUG. Other
sequences were not obviously related to any other
sequence. These motifs shared by some aptamers
maybe related to the part that binds to hTNFα. How-
ever, the secondary structure is the most important
for ligand binding.
The 20 aptamers were grouped into three major
families based on their secondary structures analyzed
by RNA structure software (Figure 2). Ligands con-
taining the secondary structure of a small unclosed
loop in the center and two stems beside the middle
loop were defined as Family I. Aptamers 3, 7, 12, 14,
16, and 18 were grouped into Family I. Ligands with
3-5 small loops bin between stems in a line were
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Table 1 Sequences of 20 RNA Aptamers for hTNFα
Family Aptamer Sequence of variable region*
I 3.1 CCCCGGGUUCUGUAUGAUCCGACCGGUCAGAUAAGACCAC
7.5 CGCAUCGUUUGCGUGGCGUGUCCGGGCGCCGAUUCGUAAA
12 CUAGGCGGAUUGUUUCGAUUCUUUGCCUUGUCCCUAGUGC
14.8 CGUAUAUACGGAUUAGGUUGUAGCUCAGACCAGUAAUGUC
16.3 CGUGCUAGAUGCUACGAGUGGUCUCCUCACGUAGAAGGGG
18.10 GGUCCCACAUAGGUUGGUCUUGUUGUAUGGGCUGUUUGCA
II 1 GUGUUUUGGGAGAGAAAAGGGGGAGCCUUUACUUUGUUGG
2 GACGAUGUUAUCAGGGAGUUGGGAUCAUAUAGUCUUACAU
4 CGCAAGAGCCGCCCUAAUGGUUCAAUGGUAACUGUAUAUG
6 GACUUCUUGUGCCAUUAUGAAUUAUUGCUAAUCCUCUUGA
8.6 AGGACGUACUUGGAAAAGAGGCGCGAAGAACCUGGUAUGU
9 UAGGACGUACUUGGAAAAGAGGCGCGAAGAACCUGGUAUG
10 UGGCCACCUUGCCACUCUUCCUUGCAUAUUUUACUCCCGC
11.7 CAAGCCGAGGGGGAGUAUCUGAUGACAAUUCGGAGCUCCA
13.2 UCAUGGUGUGUGAGUUAGCUCACGUGCCGUUUCGAAGGCG
17.9 CAUGGGCUAGACCGGCAUAAAACUGCUGUAGUUGCACGCC
19 UGGCCACCUUGCCACUCUUCCUUGCAUAUUUUACUCCCGC
20.4 CGUUGUAGUAGUGGCUUGGGCAUAACUCAGUUAAACACUA
III 5 GACCGCGGAAAAGGAAGGAAUUAGAUACAACGGAGAAGUG
15 GACCGCGGAAAAGGAAGGAAUUAGAUACAACGGAGAAGUG
*Aligned sequences isolated from the affinity-enriched RNA pools are shown. For each clone only the variable 40-nt
region is shown.
Fig. 2 Three representative secondary structures of RNA stem-loops and sequences binding to hTNFα were predicted.
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defined as Family II. Aptamers 1, 2, 4, 6, 8, 9, 10, 11,
13, 17, 19, and 20 were grouped into Family II. Lig-
ands with a big loop in the center and 2-3 stems in the
loop were defined as Family III. Aptamers 5 and 15
were grouped into Family III. We selected 10 clones
with higher affinity by ELONA (Figure 3), which were
Aptamers 3, 7, 8, 11, 13, 14, 16, 17, 18, and 20, be-
longing to Families I and II. The binding affinity of
Family II is higher than that of Family I.
Fig. 3 Binding affinity of RNA Aptamers 1–20 with
hTNFα. 5 µg/mL hTNFα was coated in every well ex-
cept blank control. 1–20: biotin-labeled RNA aptamers;
21: biotin-labeled RNA library; 22: tRNA; 23 and 24:
blank control. Biotin-labeled RNA Aptamers 1 and 2 were
added to uncoated wells.
Although possible base pairing interactions for
some ligands may be identified, generally between
the 5′-fixed sequence and nucleotides on the 3′-side
of the conserved sequence motif, no predicted sec-
ondary structure common to most of the ligands is
evident. Some of the fixed sequences in Family I were
involved in the formation of the secondary structure,
but whether the stem-loop structure formed by fixed
sequence is pivotal for the binding activity remains
unknown. It appears that some aptamers in Families
I and II formed new secondary structures, but none
in Family III did.
Nitrocellulose filter binding
The affinities of 10 truncated biotin-labeled aptamers
for hTNF were determined by filter binding. The re-
sult indicated that ligands showed very high affin-
ity for hTNFα. Removal of fixed sequence didn’t
decrease their affinity. The fixed sequence of the
10 aptamers does not contribute to the protein-
oligonucleotide binding interaction.
ELONA test
To determine the affinities of different concentration
aptamers for hTNFα, ELONA was performed as de-
scribed in Materials and Methods. The concentra-
tions of biotin-labeled RNA aptamers were from 800
nM to 50 pM (Figure 4). The result indicated that
the biotin-labeled RNA library had low binding affin-
ity for hTNFα, but RNA Aptamers 3.1, 13.2, 16.3,
20.4, 7.5, 8.6, 11.7, 14.8, 17.9, and 18.10 had high
binding affinity. RNA Aptamers 13.2, 7.5, 11.7, and
14.8 had higher binding affinity than the others, and
800 pM of RNA Aptamer 11.7 could get positive sig-
nals. So the RNA aptamer is available for detecting
hTNFα.
Inhibition of hTNFα-mediated cytotox-
icity
As shown in Figure 5, no inhibition was observed
with equimolar concentrations of RNA library for
the identification of antagonists of hTNFα activities.
RNA Aptamers 3.1, 13.2, 16.3, 20.4, 7.5, 8.6, 11.7,
14.8, 17.9, and 18.10 with high affinity for hTNFα
showed a clear inhibitory effect on hTNFα-induced
cytotoxicity, and the cytotoxicity in vitro is in a dose-
dependent fashion. RNA Aptamers 13.2, 7.5, 11.7,
and 14.8 showed higher inhibition effect on hTNFα-
induced cytotoxicity. 1 nM aptamer is enough to in-
hibit the cytotoxicity. We found that there is no sim-
ilarity between the RNA aptamer sequences and the
gene of hTNFα. This suggests that the identified se-
quence is likely to bind to hTNFα and inhibit the
binding of hTNFα to its receptor.
Size minimization
To prepare an aptamer for in vivo experimentation,
we made three alterations: size minimization, further
stabilization against nuclease activity, and incorpo-
ration of a bioconjugation handle for addition of bi-
otin. Ideally, such changes maintain the affinity and
specificity of the aptamer. Reducing the size of the
RNA resulted in a few changes to the sequence com-
pared with the initial clone; the stem was shortened
and changes were made in the stem to optimize both
transcription and stability. To identify the minimal
sequence elements that confer high binding affinity for
hTNFα, we used predictions based on conserved sec-
ondary structure motifs to derive truncated aptamers
with high affinity from the oligo, and totally got four
such aptamers (Table 2). The secondary structure
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Fig. 4 Binding affinity of random sequences of 10 RNA aptamers for hTNFα. 1–10: biotin-labeled RNA Aptamers
3.1, 13.2, 16.3, 20.4, 7.5, 8.6, 11.7, 14.8, 17.9, and 18.10; 11: biotin-labeled RNA library. 5 µg/mL hTNFα was coated
in every well. The binding affinity for hTNFα was determined by ELONA. The concentrations of biotin-labeled RNA
aptamers were from 800 nM to 50 pM.
Fig. 5 Protection of RNA aptamers to L929 cell destructed by TNF. 1–10: RNA Aptamers 3.1, 13.2, 16.3, 20.4, 7.5,
8.6, 11.7, 14.8, 17.9, and 18.1; 11: RNA library. The cytotoxic effect of hTNFα was assayed on L929 cell line. The
concentrations of biotin-labeled RNA aptamers were from 800 nM to 800 pM.
Table 2 Sequences of Four Truncated RNA Aptamers for hTNFα
Aptamer Sequence*
T1.7.5 CGCAUCGUUUGCGUGGCGUGUCCGGGCGCCGAUUCGUAAA
T2.13.2 UCAUGGUGUGUGAGUUAGCUCACGUGCCGUUUCGAAGGCG
T3.11.7 CAAGCCGAGGGGGAGUAUCUGAUGACAAUUCGGAGCUCCA
T4.14.8 CGUAUAUACGGAUUAGGUUGUAGCUCAGACCAGUAAUGUC
*The truncated aptamers are shown in black and the deleted are in gray.
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showed that there were two types of the ap-
tamer structures (Figure 6). The truncated four
clones T1.7.5, T2.13.2, T3.11.7, and T4.14.8 came
individually from Aptamers 7.5, 13.2, 11.7, and 14.8.
Their binding affinity and biological effect changed
after truncation. The sequence of the 30-nt fragment
with high affinity, named T1.7.5, encompassed the
conserved sequence motif, and an oligonucleotide cor-
responding to the selected fragment (10 nucleotides
of 3′-end truncated aptamer derived from oligonu-
cleotide 7.5) showed an approximately 3-fold loss in
binding affinity for hTNFα relative to the full-length
ligand. Further truncation at the 3′- or 5′-end of this
molecule caused a precipitous loss in affinity. The
resultant 30-nt aptamer T2.13.2 included all of the
consensus secondary structure motifs. In contrast, up
to 9 additional nucleotides could be removed from the
5′-end with little or no effect on binding affinity. The
resultant 28-nt aptamer T3.11.7, with 11 nucleotides
of 5′- and 3′-end truncated aptamer, derived from
clone 11.7. They not only have the same secondary
structure but also the same affinity as the initial full-
length oligonucleotides. Deletion of 11 nucleotides
from 5′-end and 1 nucleotide from 3′-end of aptamer
reduced the length of the putative stem. For the 29-nt
aptamer T4.14.8, removal of an additional base pair
from the base of the proposed stem (6 nucleotides of
5′-end and 5 of 3′-end derived from clone 14) did not
affect the binding affinity.
Fig. 6 Predicted secondary structures of the truncated aptamers, T1.7.5, T2.13.2, T3.11.7, and T4.14.8, which indi-
vidually came from 7.5, 13.2, 11.7, and 14.8.
Further nuclease stabilization
For RNA aptamers, a 2′-NH2 or 2′-F group replaced
the ribose 2′-OH group of pyrimidines. After that the
binding affinity assay was carried out. The results
indicated that the binding affinity of modified RNA
aptamer decreased (Figure 7). The binding affin-
ity of truncated aptamer T1.7.5 modified by 2′-NH2-
pyrimidine was higher than that of 2′-F-pyrimidine.
The half-life of these modified aptamers in serum was
increased, compared to the typical half-life of 5 min
or less for natural RNA molecules. Increased stability
of 2′-NH2-modified and 2′-F-modified RNAs was ob-
served with selected aptamers for hTNFα. The stabil-
ity of RNA aptamer T3.11.7 was examined in mouse
serum at 37℃ from 0 to 16 h. Samples were taken
at 0, 1, 2, 4, 8, and 16 h. ODtest/ODundigest was
calculated to describe the stability of oligonucleotides
(Figure 8). After 1 h, 80% of unmodified T3.11.7 were
degraded. The results indicated that the half-life of
unmodified RNA aptamer was several minutes, while
the half-life of modified RNA aptamer was prolonged
to 8 h.
Inhibition of hTNFα-mediated cytotox-
icity by minimized and modified ap-
tamers
The original and NH2-modified RNA aptamers
T3.11.7 were transcribed in vitro by T7 polymerase
and used to test their ability to inhibit hTNFα-
induced cytotoxicity. Both RNA aptamer T3.11.7
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Fig. 7 Binding affinity of modified RNA aptamers. Trun-
cated aptamers T3.11.7 and T2.13.2 were modified by 2′-
F-pyrimidine and 2′-NH2-pyrimidine. Modified aptamers
were labeled by biotin, and 5 µg/mL hTNFα was coated
in every well. The binding affinity for hTNFα was deter-
mined by ELONA. The concentrations of biotin-labeled
RNA aptamers were from 800 nM to 50 pM.
Fig. 8 Comparision of the stability of unmodified and
2′-NH2-pyrimidine modified RNA in human serum. Un-
modified RNA T3.11.7 and 2′-NH2-pyrimidine modified
RNA corresponding to it in sequence were prepared by
in vitro transcription from the same synthetic DNA tam-
plate. Both RNAs were internally biotin-labeled and in-
cubated at a concentration of 50 nM 85% human serum
supplemented with 10 mM phosphate buffer (pH 7.4).
Aliquots from unmodified and 2′-NH2-pyrimidine modi-
fied RNA incubation mixtures were withdrawn at indi-
cated time intervals, frozen in dry ice until the end of
the experiment, and loaded onto 20% denaturing poly-
acrylamide gels to resolve labeled degradation products.
Absorbance of purified RNA was detected at 260 nm, and
ODtest/Odundigest(%) were calculated.
A B
Fig. 9 A. Inhibition of hTNFα-induced cytotoxicity in L929 cell by RNA aptamer T3.11.7 and 2′-NH2-modified
aptamer T3.11.7. The concentrations of RNA aptamers were from 300 nM to 1 nM. Each concentration of hTNFα
and aptamer mixture was tested in triplicate. B. Inhibition of 1 or 10 U hTNFα-induced cytotoxicity in L929 cell by
RNA aptamer T3.11.7. The cytotoxic effect of the hTNFα was assayed oh L929 cell line. The concentrations of RNA
aptamers were from 800 nM to 800 pM. Each concentration of hTNFα and aptamer mixture was tested in triplicate.
38 Geno. Prot. Bioinfo. Vol. 2 No. 1 February 2004
Yan et al.
and NH2-modified aptamer T3.11.7 showed a clear
inhibitory effect on hTNFα-mediated cytotoxicity in
L929 cells, whereas no inhibition was observed when
equal concentrations of RNA library were tested (Fig-
ure 9A). Both T3.11.7 aptamers inhibited the cytotox-
icity in a dose-dependent fashion. The inhibition rate
of original T3.11.7 is 50%-100%, while that of NH2-
modified T3.11.7 is 20%-90%. The result showed that
the biological activity decreased after modification.
Serially diluted modified RNA aptamer T3.11.7
was preincubated with 1 U and 10 U hTNFα (Figure
9B). The results indicated that the levels of inhibition
by modified T3.11.7 depend on the concentrations of
used hTNFα. It can inhibit 1 U hTNFαeffectively,
but for 10 U hTNFα, the inhibitory decreased.
The aptamers selected in this study could inhibit
hTNFα-mediated cytotoxicity in vitro on mouse cell
lines. As the binding of hTNFα to its receptors is a
prerequisite for its biological activities, the ability of
the aptamers to inhibit hTNFα-induced cytotoxicity
suggests that it mimics the binding site of hTNFα
membrane receptor.
Discussion
Previous work has shown that the approach to in-
hibit the binding of hTNFα and its receptor can re-
duce the cytotoxicity of hTNFα (11 ). So our studies
have focused on the identification of RNA aptamers
binding to hTNFα. In order to identify a physiolog-
ically active, nuclease-stabilized aptamer that inhib-
ited the function of hTNFα in vitro, we got 20 oligonu-
cleotides that were truncated to the minimal sequence
capable of their binding affinity for hTNFα (28–31
nt) and were further modified by 2′-F-pyrimidine and
2′-NH2-pyrimidine where the substitution was toler-
ated. Furthermore, one 2′-NH2-modified aptamer is
able to significantly inhibit hTNFα-mediated cyto-
toxicity in mouse fibroblast cell line L929. Results
demonstrate that the aptamers potently inhibit the
binding of hTNFα to the receptors.
The 20 oligonucleotides with high affinity for
hTNFα were sequenced and no identical sequence was
found. Their secondary structure was analyzed by
RNA structure software. The data indicated that the
secondary structure is the most important for the lig-
and binding. Molecular recognition of nucleic acids
can arise by virtue of binding specificity at the level
of primary and secondary structure; however, it is at
the level of tertiary structure that the highest level
of selectivity with non-nucleotide ligands should be
achieved. Single strand of RNA that are folded into
complex secondary and tertiary conformations, in-
cluding local regions of duplex structure, may be dis-
torted as a result of base mismatches, bulges, pseudo-
knots, and hairpins. The binding affinity of oligonu-
cleotides is based on the secondary and tertiary struc-
tures.
In this report, biotin-labeled UTPs were incorpo-
rated by in vitro transcription with the ratio of UTPs
to biotin-UTPs as 2:1. The result of ELONA was
calculated according to the number of UTPs. Since
almost all the oligonucleotides have the same number
of UTPs, we can use them to determine the binding
affinity of aptamers for hTNFα. Aptamers promise to
be smaller in size and less complex than antibodies,
easy to manufacture and modify, chemically consis-
tent between lots, compatible with most current assay
formats, and stable during storage (12 ).
A cloned aptamer sequence is typically 70–80 nt
in length. Because reduced size may lead to increased
tissue penetration rates (13 ), make these aptamers
clear from the blood more rapidly than the full-length
aptamer, which is an advantage for in vivo imaging,
and will lead to more efficient chemical synthesis, we
focused on size reduction. It is desirable to identify
the minimal high-affinity aptamer sequence. Gener-
ally, the 5′-fixed and 3′-fixed sequences have no pre-
dicted secondary structure common to most of the lig-
ands. The results of ELONA and SPR demonstrated
that truncated oligonucleotides bound to hTNFα with
the same affinity as originals.
To be applicable in cell culture studies, we gener-
ated nuclease-resistant aptamers in which all pyrim-
idine residues were substituted by 2′-NH2- and 2′-F-
modified monomers. This modification is known to
protect the majority of serum nucleases so that such
aptamers can be applied in the presence of biolog-
ical materials in which normal RNA would rapidly
degrade (14 ). Four truncated aptamers were modi-
fied by 2′-F and 2′-NH2, followed by affinity analy-
sis. We found affinity reductions in all modified oligo-
nucleotides. The affinity of the 2′-NH2-pyrimidine
hTNFα aptamers was indeed higher than that of most
2′-F-pyrimidine ligands. The stability of RNA ap-
tamers in mouse serum was enhanced.
In pathological conditions caused by excessive pro-
duction of hTNFα, such as in rheumatoid arthritis or
septic shock, the neutralization of high-level hTNFα
using anti-hTNFα monoclonal antibodies (mAb) or
recombinant forms of soluble hTNFα receptors might
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be the strategy of choice. However, the use of these
approaches has several limitations: chimerical or hu-
manized mAb, after repeated administrations, might
induce a neutralizing antibody response resulting in
less effective treatment. hTNFα is a trimer molecule,
and for its effective inhibition, at least two molecules
of the hTNFα receptor, expressed as fusions with the
immunoglobulin G molecule, are required (15 ). In
the case of recombinant forms of soluble hTNFα re-
ceptors, these molecules can be unstable in vivo, im-
munogenic, and could exert an agonistic effect by act-
ing as hTNFα carriers. The use of low-molecular-
weight synthetic peptides as antagonistic molecules is
another approach, but they have only low affinity and
biological effect. So aptamer might be a suitable al-
ternative for the in vivo blockade of hTNFα. In vitro,
the modified hTNFα aptamers inhibit the binding of
hTNFα to cell surface hTNFα receptors expressed on
L929 cells. Thus, the aptamers that specifically in-
hibit hTNFα may have great utility in combating a
variety of hTNFα human diseases.
Materials and Methods
Reagents
Recombinant hTNFα was prepared by our labora-
tory. The protein was resuspended in phosphate-
buffered saline (PBS) to a concentration of 1 µg/µL
and stored at –20℃ in small aliquots before use.
Aliquots were stored at 4℃ for up to 4 weeks af-
ter thawing. 2′-F- and 2′-NH2-pyrimidine nucleot-
riphosphates were purchased from Ambion (Austin,
USA). T7 Riboprobe kit was purchased from Promega
(San Luis Obispo, USA). HATF membrane was
purchased from Millipore (Bedford, USA). Purifi-
cation system was purchased from Qiagen (Valencia,
USA). DNA oligonucleotide template libraries 5′-
GGGAGGACGATGTTA(N)40AAGAAGACTCGCA
AGA-3′ (N means any nucleotide) were pre-
pared by chemical synthesis. T7 RNA poly-
merase promoter sequence localized at the 5′-
end of each template. Oligonucleotide primers
(Primer 1: 5′-GGGAGGACGATGTTA-3′; Primer
2: 5′-TCTTGCGAGTCTTCTT-3′; Primer 3:
5′-TAATACGACTCACTATA-3′; Primer 4: 5′-
TAATACGACTCACTATAGGGAGGACGATGTTA-
3′) were synthesized by Takara (Dalian, China) for
template amplification and reverse transcription.
Double-stranded DNA templates were prepared by
annealing Primers 1 and 2 to the libraries and extend-
ing the primers using MLV virus reverse transcriptase
(Biolabs, Beverly, USA) at 37℃. 1 nmol of RNA li-
brary was synthesized by in vitro T7 transcription
from the PCR-amplified double-stranded DNA pool.
RNAs were purified from denaturing (7 M urea) poly-
acrylamide gels by excising and crushing the gel slice
containing the RNA and soaking it for several hours
or overnight in 2 mM EDTA. Approximately 5 nmol
of RNA was obtained from each transcription.
The SELEX protocol
The SELEX process of affinity selection followed by
amplification of the selected pool has been described
in detail (16 ). In brief, one round of selection and
amplification was performed as follows. hTNFα was
mixed with RNA in binding buffer of PBS with 1 mM
MgCl2 and 10 mM DTT. After incubation at 37℃
for 30 min, the mixture was passed through 0.45-µm
Type HATF nitrocellulose filters to collect complexes
of hTNFα with RNA. Then RNAs were eluted from
the filters by eluting buffer (binding buffer with 10
mM EDTA) and incubated in a 2:1 mixture of phenol
(pH 7) and 7 M urea. After precipitation from the
aqueous phase, RNAs were annealed to Primer 2 and
reverse transcribed using MLV reverse transcriptase.
The resultant cDNAs were amplified with 15 cycles of
PCR using Primers 2, 3 and 4. Transcription of the
PCR product that yielded a new library enriched for
sequences with affinity for hTNFα.
Cloning and analysis of oligonucleotides
After 12 rounds of selection and amplification, indi-
vidual molecules in the selected pools were cloned
with pGEM-T Vector (Promega). Standard trans-
formation was performed. Colonies grown on agar
plates were picked randomly for culture. The plasmid
in each colony was prepared using QIAwell Plasmid
Purification System and sequenced by Takara. The
primary structure sequences were analyzed by Macaw
2.05 software and conservative sequences were found.
The secondary structure was predicted by RNA struc-
ture 3.5 software, which is based on the theory of the
smallest free energy, Zuker algorithm. Sequences were
grouped into families according to their different sec-
ondary structures.
Nitrocellulose filter binding
Nitrocellulose filter binding was used to assess ap-
tamer affinity for hTNFα. Biotin-labeled UTPs were
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incorporated by in vitro transcription with the ratio
of UTPs to biotin-UTPs as 2:1. The results of filter
binding assay and ELONA were calculated accord-
ing to the number of UTPs. Then we incubated the
labeled aptamers in low concentrations (typically less
than 70 pM) with various concentrations of hTNFα or
without proteins in binding buffer at 37℃ for 30 min.
Samples were dotted on prewashed 0.45-µm nitrocel-
lulose filters followed by a 5-10 mL wash with binding
buffer. Filters were incubated with HRP-Streptavidin
after blocked with 1% BSA (bovine serum albumin).
The fraction of RNA that bounds to protein was mea-
sured by OPD substrate.
ELONA test
Microtiter plate was coated overnight at 4℃ with 50
µL/well of a 5 µg/mL solution of the hTNFα dis-
solved in 0.1 M NaHCO3, pH 9.0. After 3 times wash-
ing with PBS/Tween, the plate was blocked for 2 h
at 37℃ with 100 µL PBS containing 1% BSA in each
well. Following 3 times washing with PBS/Tween, the
diluted RNA aptamers were added to wells and incu-
bated at 37℃ for 30 min. After 3 times washing with
PBS/Tween, 50 µL diluted Horseradish Peroxidase
conjugated streptavidin was added to each well and
the incubation was washed. Then TMB and H2O2
were added. The plate was developed at room tem-
perature for 10 min and read at 450 nm wave length.
Optimization of high affinity RNA ap-
tamers
Aptamers that come out of a SELEX experiment are
full-length sequences containing the fixed sequences
that were included to aid the amplification process.
These full-length aptamers are generally 70–80 nt
long and could be truncated to eliminate nucleotide
stretches that are not important for direct interaction
with the target or folding into the structure that facil-
itates target binding. The identification of truncated
aptamers restricted to the minimal target-binding do-
main requires more effort, while it has been success-
fully carried out to obtain functional aptamers less
than 40 nt long (17 ).
In the majority of cases, the fixed sequence re-
gions used for primer binding are unimportant for
aptamer function and can be eliminated, thereby pro-
ducing short aptamer sequences. Aptamers could be
truncated and modified with high affinity. The DNA
template of truncated RNA aptamer was chemically
synthesized and transcribed by T7 RNA polymerase,
then the binding affinity was detected. Whether fur-
ther truncation should be done was decided by what
the result was. At last, we got the truncated oligonu-
cleotide that retained an affinity for hTNFα equiva-
lent to that of the full-length one.
Stability of aptamers in mouse plasma
in vitro
The stabilities of RNA-based aptamers in vitro were
examined in rat serum at 37℃ . Fresh serum was ob-
tained from a Balb/c mouse’s eyes and was treated
with 20 mmol/L sodium phosphate buffer. Test lig-
ands were added to the serum to the final concen-
tration of 300 nmol/L. The final serum concentration
was 85% as a result of the addition of buffers and ap-
tamers. From the original 100 µL incubation mixture,
20 µL aliquots were withdrawn at various periods and
added to 2 µL of 500 mmol/L EDTA (pH 8.0), respec-
tively. The mixtures were then frozen in dry ice and
stored at –20℃ until the end of the experiment. After
purification, half of the sample was analyzed by PAGE
and stained by AgNO3, the rest was detected at 260
nm wavelength. ODtest/ODundigest were calculated to
describe the stability of oligonucleotides.
Inhibition of hTNFα-mediated cytotox-
icity
The mouse fibroblast cell line L929 were cultured in
RPMI 1640 medium (Gibco, New York, USA) sup-
plemented with 10% (V/V) heat inactivated FCS
(foetal calf serum) and antibiotics (100 U/mL peni-
cillin, 100 µg/mL streptomycin). The cytotoxic effect
of the hTNFα was assayed on L929 cell line. Cells
were plated into 96-well flat bottomed microtitre
plates (Nunc, Roskilde, Denmark) at 2×105/mL of
the culture medium at 37℃ in the presence of 5%
CO2 incubator for 24 h. Serially diluted RNA ap-
tamers in the same culture medium were preincu-
bated with a constant amount of hTNFα at 37℃
in the presence of 5% CO2 incubator for 1 h. The
mixture was plated in triplicate in the cells in the
presence of 2 µg/mL actinomycin D and incubated
at 37℃ for 24 h in the presence of 5% CO2 incu-
bator. Viable cells were stained after incubation
with 500 µg/mL MTT (thiazolyl-blue) at 37℃ for
4 h. Then, 1% SDS (pH 4.5) was added. Ab-
sorbance of each well was read at 570 nm wave
length. Inhibition rate was calculated by the formula:
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Inhibition(%) = [(ODtest −ODhTNFα)/(ODcontrol−
ODhTNFα)] ∗ 100.
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